Skip to main content
Premium Trial:

Request an Annual Quote

Ambry Genetics, Cell Line Genetics Ink Sales Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cell Line Genetics will sell Ambry Genetics' StemArray aCGH product and related services under an agreement announced today.

Madison, Wis.-based CLG will sell the StemArray products and services to its current customers and other companies and research institutions. CLG will offer the StemArray services through its own labs.

The StemArray uses array comparative genomic hybridization and covers more than 60 stem cell-associated genes and more than 200 cancer-related genes. It is specifically designed for stem cell scientists working with human embryonic stem cells and induced pluripotent stem cells who require a higher-throughput technology to "detect genetic gains and losses that might be missed by lower resolution g-banded karyotyping," Ardy Arianpour, VP of business development for Aliso Viejo, Calif.-based Ambry Genetics, said in a statement.

"Cell Line Genetics has the depth and breadth of experience to help us shift sales of the Ambry StemArray into high gear," said Arianpour. "Our scientific expertise combined with Cell Line Genetics' strength in the karyotyping market should make for a strong synergistic partnership."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.